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SURFACTANT ENHANCED DELIVERY OF C/EBP HOMOLOGOUS PROTEIN AND ANGIOPOIETIN 2 
SILENCING RNA TO PREVENT BRONCHOPULMONARY DYSPLASIA IN MOUSE LUNG. John G. Ramirez, 
Mansoor A. Syed, Vineet Bhandari. Section of Neonatal-Perinatal Medicine, Department of Pediatrics, 
Yale University, School of Medicine, New Haven, CT. 
Objective.  To determine if poractant alfa (Curosurf®) could serve as a viable vehicle for silencing RNA 
(siRNA) delivery. Specifically, we hypothesize that use of Curosurf® as an enhanced delivery vehicle for 
C/EBP homologous protein (CHOP) and Angiopoietin 2 (Ang2) siRNA would augment gene silencing, 
preventing cell death and bronchopulmonary dysplasia (BPD) in the mouse lung. 
Design.  Transfection efficiency of Curosurf® was compared to naked siRNA and Lipofectamine 2000®. 
MLE-12 cells were transfected with CHOP and Ang2 siRNA using Curosurf®, then exposed to hyperoxic 
conditions. Cultures were evaluated for respective protein expression and markers of cell death. 
Curosurf® enhanced siRNA therapy was tested in a hyperoxia-induced mouse model of BPD. Protein 
expression and lung morphology were assessed and compared to naked siRNA. 
Results.  Curosurf® significantly improved cell transfection rates when compared to naked siRNA 
alone. Cell cultures treated with Curosurf® enhanced CHOP and Ang2 siRNA delivery had significantly 
lower levels of expression of their respective protein products. Cleaved caspase 3, a marker of cell 
death, was also decreased in cells transfected using Curosurf®. Curosurf® enhanced delivery of Ang2 
siRNA had a modest, but significant, improvement in mouse lung morphology in a hyperoxia-induced 
model of BPD. 
Conclusions.  Curosurf® enhances silencing RNA delivery of C/EBP homologous protein and 
Angiopoietin 2, resulting in an improvement in mouse lung phenotype in a hyperoxia-induced model 
of BPD.  
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Prior to the introduction of the mechanical ventilator to the neonatal intensive care unit 
in the 1960s, premature infants with respiratory distress syndrome (RDS) either died 
within the first week of life or survived with respiratory sequelae. In 1967 Northway et al 
described a new syndrome that affected premature infants with RDS who received 
prolonged treatment of high concentrations of supplemental oxygen via mechanical 
ventilation with high peak inspiratory pressures.1 The surviving infants of this cohort had 
a mean gestational age of 34 weeks and a mean birth weight of 2.3kg. This form of chronic 
lung disease was characterized by an oxygen requirement at 28 days of life and 
progressive radiographic changes. 
The syndrome was coined as bronchopulmonary dysplasia (BPD) in order to emphasize 
the fact that the disease process effected all tissues of the lung. Hyperinflation and 
atelectasis, along with a cystic and scarred lung appearance were characteristic findings 
on chest x-ray. Pathologic examination was characterized by smooth muscle hypertrophy, 
inflammatory infiltrates, interstitial fibrosis, and emphysema. These patients frequently 
remained oxygen and ventilator dependent beyond the initial few weeks of life and 
developed chronic lung changes and abnormal pulmonary function. Infants with severe 
lung damage had a high mortality secondary to progressive respiratory failure, usually 
within the first weeks of life. 
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To study the long-term sequelae Northway et al conducted a follow up study of their 
original cohort.2 Most of these adolescents and young adults had some degree of 
pulmonary dysfunction characterized by airway obstruction, airway hyperreactivity, and 
hyperinflation. Approximately a quarter of the patients in this cohort had severe 
pulmonary dysfunction, including persistent symptoms of respiratory difficulty. 
The “New” BPD 
Preterm delivery affects 12.5% of pregnancies in the United States. These premature 
infants are at a higher risk for complications and unique medical problems. BPD is the 
most common chronic lung disease of infancy; it persists even with advancements having 
been made in the medical management of premature infants. During the era of “classical” 
or “old” BPD, few patients survived with birth weights less than 1 kg and a gestational age 
less than 28 weeks.3 An increasing number of patients born at a younger gestational age 
are now surviving past infancy. Despite advancements in premature neonatal care the 
incidence of BPD in all preterm birth survivors has not decreased over time.4 However, 
the demographics of the patient population has changed owing to the increased survival 
of the highly premature infants, specifically very low birth weight (<1500 g) and extremely 
low birth weight infants (<1000 g), and those <30 weeks’ gestation.5 
The “new” BPD, henceforth referred to simply as BPD, is a milder form of lung disease 
compared to “classic” BPD. The diagnosis and severity of BPD are defined by specific 
diagnostic criteria.6 A clinical diagnosis of BPD for infants <32 weeks gestational age 
requires that the patient have a supplemental oxygen requirement at 28 days of life. The 
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severity of disease is defined by the supplemental oxygen need and/or respiratory 
support at 36 weeks corrected gestational age, or at the time of discharge. This can range 
from needing no supplemental oxygen to requiring positive pressure support. 
The pathology of BPD is characterized by an impairment of alveolar development, 
resulting in alveolar hypoplasia.7 Pathologic examination of infants who died with BPD 
reveals lungs with fewer number of alveoli and increased alveolar diameters.8 
Inflammation is generally milder with less fibrosis and absence of smooth muscle 
hypertrophy when compared to “old” BPD. Notably, the pulmonary microvasculature is 
also disrupted and features an abnormal vessel network with dysregulated vessel 
proliferation, dysmorphic vessels, and thickened alveolar septa.9 
The possible sequelae of BPD is still under investigation, however, the available data 
would appear to suggest significant long-term morbidity. Studies show that BPD survivors 
are likely to suffer from persistent respiratory symptoms requiring medication, although 
no correlation was found between gestational age or duration of ventilatory support.10 
Investigations of lung function in this population have revealed the development of 
substantial airway obstruction, as well as persistence of impaired alveolar 
development.3,10 These children were also more likely to suffer from chest deformities 
and asthma. Recent research has also identified pulmonary artery hypertension as a 




In order to discuss the proposed therapeutic intervention explored in this paper, it is 
important to review pertinent fetal lung development. Gaining insight into human lung 
development will assist in understanding the etiology of BPD and potential avenues for 
intervention. 
Fetal Lung Development 
Human lung development is a complex and highly regulated process involving the 
coordination between surface epithelium, supporting interstitial tissue, blood vessels, 
and numerous regulatory factors.12,13 During the first half of fetal life (embryonic phase) 
the major airways of the lung develop from the foregut. By 16 weeks’ gestation 
(pseudoglandular phase), blood vessels that supply the lung and the major conducting 
airways have formed. Through 25 weeks’ gestation (canalicular phase) the airways widen 
and lengthen, which is followed by the formation of saccules at the terminal bronchioles 
(saccular phase). The alveolar-capillary barrier undergoes reorganization, bringing the 
epithelial layer in close approximation with the capillary endothelium. By 35 weeks’ 
gestation (alveolar phase) the lung is in its final phase of development – alveolarization 
of the distal lung saccules. The result is a 4-fold increase in lung volume from 29 weeks’ 
gestation to term and a concomitant increase in available surface area for gas exchange. 
This maturation also coincides with a reduction of interstitial tissue, which serves to 
facilitate effective diffusion of gases. Lung development continues in the months and 




During the late canalicular/early saccular phase (25-35 weeks’ gestation) the cuboidal 
epithelium is replaced by simple squamous epithelium. Ninety-five percent of the alveolar 
surface is composed of Type I epithelial cells with Type II epithelial cells making up the 
remainder (although Type II pneumocytes dominate in numbers overall – 60%).15 Type II 
pneumocytes serve as progenitor cells; they retain the capacity to divide and differentiate 
when Type I cells become damaged.16 Type II epithelial cells are also responsible for 
producing and elaborating surfactant, a lipoprotein complex that lowers surface tension 
at the air-water interface, thereby preventing alveolar collapse during expiration. 
Lamellar bodies appear within Type II cells at 24 weeks’ gestation, concomitant with the 
initiation of surfactant production, and are responsible for storing the lipoprotein 
complex. However, adequate amounts of surfactant are not produced until 35 weeks’ 
gestation.17 Type I epithelial cells are specialized to facilitate the diffusion of gases across 
the alveolar-capillary barrier. Organelles within these cells are clustered around the 
nucleus, resulting in a highly attenuated endothelial lining. Pinocytotic vesicles can be 
found within the cytoplasm of this thin portion, which are thought to play an important 
role in the turnover of surfactant.18 However, surfactant reuptake is thought to be chiefly 
mediated by Type II cells via surfactant protein (SP) mediated endocytosis.19-22 
Pathogenesis of BPD 
Early investigations into the etiology of the “old” BPD hypothesized that the 
pathophysiology was due to oxygen toxicity and baro/volutrauma from mechanical 
ventilation.23,24 Later studies in newborn mice demonstrated that exposure to oxygen 
alone could account for many of the changes seen in patients with BPD.25,26 When these 
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mice were exposed to continuous atmospheric conditions of hyperoxia they developed 
an impairment of lung development, specifically a decrease in alveolarization and mild 
inflammatory response. It is postulated that hyperoxic acute lung injury (HALI) is 
mediated by reactive oxygen species, both from high oxygen ventilation and 
inflammatory cells, which activate extrinsic and mitochondrial cell death pathways, 
resulting in cell death with features of necrosis.27 
BPD is a disease that effects newborn infants and involves the impairment of normal lung 
growth and development. The hallmark of the disease is impaired alveolarization. As 
stated above, premature infants comprise the patient population of BPD as it exists today. 
These premature infants are born with underdeveloped lung anatomy that is deficient in 
proper alveolar numbers and biochemical activity. The architecture of the lung is 
unoptimized for efficient gas exchange at the alveolar-capillary barrier, while surfactant 
production is inadequate to prevent alveolar collapse. As mentioned previously, lung 
development is a complex and highly coordinated process – thus BPD is likely the result 
of interference with the formation of terminal respiratory airways, alveoli, and 
microvasculature that supplies these areas.12 
The etiology of BPD as we know it today is multifaceted, with multiple major inciting 
factors acting synergistically to develop the disease state. Preterm neonates are more 
susceptible to developing chronic lung disease as they are born with a surfactant 
deficiency secondary to immature Type II alveolar cells. The use of invasive, prolonged 
mechanical ventilation causes direct damage to the nascent alveoli which have limited 
repair capacity. Because the pulmonary antioxidant system develops alongside the 
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surfactant system, high levels of supplemental oxygen can cause significant oxidative 
stress injury.17 Additionally, perinatal sepsis (specifically chorioamnionitis) has been 
shown to be a risk factor for BPD after premature birth.28 
The common thread among these stressors is injury to the developing alveolar epithelium 
with subsequent release of proinflammatory cytokines, chemotactic factors, and an 
increase in microvascular permeability. The result is initiation of an inflammatory 
response, a process that is known to interfere with formation of the microvasculature and 
alveolarization in the developing lung.29,30 An imbalance of inflammatory mediators 
causes the activation of cell death pathways followed by resolution and repair. It is this 
process which disrupts normal lung architecture and results in the characteristic features 
of impaired alveolarization and dysregulated angiogenesis.6 
Various biomarkers are associated with BPD including regulatory factors, angiogenic 
factors, inflammatory mediators, and markers of oxidative injury.31 Although not yet 
routinely used in clinical practice, these biomarkers offer potential avenues of 
intervention if they are indeed found to be in a causal relationship with BPD. Therefore 
they are of particular research interest. For the purposes of this paper we will focus on 
C/EBP homologous protein (CHOP) and Angiopoietin 2 (Ang2), two biomarkers thought 
to be involved in the cascade of events leading to dysregulated alveolar development. 
Importance of CHOP and Ang2 
In addition to the aforementioned extrinsic and mitochondrial cell death pathways, a 
third pathway exists which involves the endoplasmic reticulum (ER). Known as the ER 
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stress-dependent pathway, this pathway reacts to accumulated unfolded proteins within 
the ER by facilitating either improvement in protein folding and processing or inducing 
apoptosis.32 This unfolded protein response (UPR) is dependent on the nature of the 
inciting stressor. Moreover, the UPR appears to upregulate the expression of genes that 
are protective against oxidative injury.33 This implies that reactive oxygen species play a 
significant role in the ER stress-dependent cell death pathway. CHOP acts as an important 
late-phase mediator in this pathway, with increased levels of CHOP protein favoring cell 
death.32 
Angiogenesis plays a fundamental role in embryonic and postnatal organ development. 
Vascular formation is regulated by growth factors and cytokines, including a family of 
vascular growth factors called angiopoietins. Angiopoietins are ligands of the tyrosine 
receptor kinase receptor with immunoglobulin and epidermal growth factor homology 
domain 2 (Tie2) located on endothelial cells.34 Through this interaction they modulate the 
remodeling of blood vessels. Furthermore, angiopoietins can also induce the formation 
of new blood vessels when working in concert with vascular endothelial growth factor 
(VEGF). 
Angiopoietin 1 (Ang1) is a Tie2 receptor agonist. It enhances angiogenesis, induces 
vascular maturation, and stabilizes blood vessels thereby decreasing vascular leak. Ang2, 
on the other hand, is a Tie2 receptor antagonist. It destabilizes blood vessels, induces 
vascular regression, and induces endothelial cell apoptosis.27 Hence spatial and temporal 
regulation of Ang1 and Ang2 expression plays a key role in pulmonary vascular network 
development.35 Indeed, tracheal aspirates from very preterm infants who go on to 
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develop BPD have been found to contain relatively high levels of Ang2, suggesting an 
association with abnormal fetal pulmonary angiogenesis.9,36 Furthermore, hyperoxia has 
been shown to be a potent inducer of Ang2 mRNA and protein with resultant HALI 
(oxidative injury, inflammation, and cell death) and epithelial necrosis.27 
Advancements in Treatment 
Neonatal care has changed over the last decade following the recognition of the special 
needs of premature infants. Disease prevention starts during the antenatal course as the 
potential for developing BPD begins in utero. Tocolytics and antenatal corticosteroids can 
protect against respiratory distress by delaying delivery and allowing for lung maturation 
to occur.17,37 Surfactant replacement therapy has also played a pivotal role in increasing 
patient survival by bridging the gap between birth and adequate endogenous surfactant 
production.38 Exogenous surfactant therapy and gentle ventilation techniques have 
served to reduce the incidence of stretch injury. The use of lower oxygen concentrations 
for resuscitation, as well as administration of antioxidants such as vitamin A, has been 
shown to reduce oxidative stress in the newborn.5,39 Aggressive treatment and prevention 
of infection is also important, as perinatal infection has been associated with an increased 
risk of developing BPD.40 Postnatal corticosteroids have been shown to improve 
outcomes in some studies, presumably by stimulating surfactant production, enhancing 
antioxidant enzyme synthesis, and suppressing the inflammatory response to injury.41 
The common theme in treatment is the prevention of inflammation, thus protecting from 
cellular death and promoting normal lung development.5 In keeping with this theme, one 
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option that has been explored is the use of short interfering RNA, also known as silencing 
RNA (siRNA), to inhibit cell death pathways. Antisense agents, such as siRNA, are used by 
eukaryotic organisms to regulate gene expression via the prevention of translation. The 
cornerstone of this regulatory pathway involves the conjugation of a strand of siRNA to 
proteins of the Argonaute family, thereby forming an RNA-induced silencing complex 
(RISC).42 RISCs are effector complexes that are responsible for silencing complementary 
single stranded RNA sequences through activation of ribonuclease (RNase).43 
Recent studies have demonstrated that administration of CHOP and Ang2 siRNA have 
beneficial effects in cell and animal models. CHOP siRNA has been shown to prevent cell 
death in alveolar epithelial cells and hyperoxia-induced murine models of BPD.44 
Additionally, in vivo BPD models treated with CHOP siRNA benefited by preserved 
alveolarization.44 Bhandari et al demonstrated that administration of Ang2 siRNA in vivo 
reduced hyperoxia-induced inflammation and cell death.45 Both these studies were 
carried out with the use of a transfection reagent in vitro and naked siRNA alone in vivo. 
The numerous phosphate groups in RNA are charged at physiologic pH, giving the 
molecule an overall negative charge. This would make entry of siRNA into cells difficult as 
ionic substances generally cannot cross the lipophilic plasma membrane. Thus, 
transfection reagents are commonly used in cell cultures as internalization of naked 
oligonucleotides is usually inefficient.43 Typical transfection reagents are lipid-derived, 
cationic substances capable of forming liposomes that are specifically designed to deliver 
exogenic nucleic acids into eukaryotic cells.43 However, these products are only used in 
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cell culture experiments. They are not cleared for use in the clinical setting and can have 
considerable cytotoxic effects.46 
Surfactants are lipoprotein substances that readily form liposomes in aqueous 
solution.47,48 Curosurf® (Cornerstone Therapeutics Inc, Cary, NC) is an extract of natural 
porcine lung surfactant consisting of 99% polar lipids and 1% hydrophobic low molecular 
weight proteins including SP-B and SP-C, but not SP-A.49 It is routinely used in the 
treatment of RDS in premature infants.38,50 Of the commercially available therapeutic 
surfactants, Curosurf® has physiologic phosphatidylcholine composition most similar to 
that of human surfactant.49 Furthermore, the ultrastructural composition of Curosurf® 
consists of roughly 80% lamellar/vesicular structures.49 
Given the capacity of surfactants like Curosurf® to form liposomes, the potential for 
uptake by alveolar epithelial cells (surfactant turnover), and the obvious therapeutic 
benefits for very premature infants, we postulate that Curosurf® could serve as a viable 
vehicle for siRNA delivery. Specifically, we hypothesize that use of Curosurf® as an 
enhanced delivery vehicle for CHOP/Ang2 siRNA would augment gene silencing, 
preventing cell death and BPD in the mouse lung. Our goals in this project were to deliver 
CHOP/Ang2 siRNA using Curosurf® as the delivery vehicle in in vitro and in vivo systems 
to evaluate the impact on CHOP/Ang2 gene silencing, cleaved caspase 3 protein 
expression, and lung morphology in a hyperoxia-induced BPD mouse model.  
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Materials and Methods 
Cell Culture Work 
Cells.  Mouse transformed lung epithelial cells (MLE-12) (American Type Culture 
Collection, Manassas, VA) were cultured in DMEM supplemented with 2% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin. Cells were cultured in a humidified incubator 
under normal growth conditions of 5% CO2 at 37°C. All cell culture work was carried out 
by the author. 
Transfection fluorescence.  One microliter of 20 μM labeled, scrambled siRNA (Thermo 
Fisher Scientific, Waltham, MA) was diluted in 500 μL of DMEM. Transfection reagent – 
20 μL of Lipofectamine 2000® (Life Technologies, Carlsbad, CA) or 5/10/20 μL of Curosurf® 
(Cornerstone Therapeutics Inc, Cary, NC) – was diluted in a separate 500 μL of DMEM. 
After 5 min, both solutions were combined, briefly vortexed, and allowed to sit for 15 min 
at room temperature to permit transfection complexes to form. MLE-12 cells (2.5 × 105) 
were seeded per well in 24-well plates, in 500 μL DMEM enriched with 2% FBS. Three 
hundred microliters of transfection complex solution was then added drop-wise to 
cultures with gentle swirling to ensure uniform distribution. Cells were then incubated 
under normal growth conditions for 24 hours. Cells were then stained with DAPI (Thermo 
Fisher Scientific, Waltham, MA) and visualized using an Olympus IX70 fluorescence 
microscope with the appropriate fluorescence filters. Photomicroscopy was performed 
using cellSens imaging software (Olympus Corp), with a minimum of 3 fields per group. 
Cell counts for each image were manually performed. 
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siRNA transfection.  One microliter of 20 μM siRNA (CHOP or Ang2) (Life Technologies, 
Carlsbad, CA) was diluted in 500 μL of DMEM. Transfection reagent – 20 μL of 
Lipofectamine 2000® or 10 μL of Curosurf® – was diluted in a separate 500 μL of DMEM. 
After 5 min both solutions were combined, briefly vortexed, and allowed to sit for 15 min 
at room temperature to permit transfection complexes to form. MLE-12 cells (1 × 106) 
were seeded per 60 mm plate in 3000 μL DMEM enriched with 2% FBS. One thousand 
microliters of transfection complex solution was then added drop-wise to cultures with 
gentle swirling to ensure uniform distribution. Cells were then incubated under normal 
growth conditions for 24 hours prior to hyperoxia exposure. 
Oxygen exposure.  MLE-12 cell cultures were placed in an airtight metallic chamber (30 × 
20 × 20 cm3) containing a plate of autoclaved water to promote proper humidification. 
The chamber was flushed with 95% O2 for 5 minutes to purge the room air from the 
container. The chamber was then placed in a humidified incubator at 37°C for 16 hours. 
Protein isolation and detection.  Cell cultures were washed with cold PBS and lysed using 
radioimmunoprecipitation assay (RIPA) buffer. Following incubation, lysates were 
centrifuged and supernatant containing whole protein was collected. Western analysis 
was used to evaluate lysates. Whole protein samples were electrophoresed using 4-20% 
polyacrylamide gels and transferred to a polyvinylidene difluoride membrane. CHOP and 
Ang2 protein was detected, using β-actin as control. Cleaved caspase 3 was detected as a 
surrogate marker for cell death. CHOP antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Ang2 antibody was obtained from R&D Systems 
(Minneapolis, MN). β-actin and cleaved caspase 3 antibodies were purchased from Cell 
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Signaling Technology (Danvers, MA). Detection of protein-bound antibody was achieved 
using enhanced chemiluminescence. Protein levels were evaluated by densitometry using 
ImageJ (National Institutes of Health). 
Animal Work 
Animals.  Wild-type (WT) C57BL/6 mice were obtained from Jackson Laboratories (Bar 
Harbor, ME). Animals were kept at atmospheric pressure and room temperature, 12-hour 
light-dark cycle, and allowed to feed ad lib. Two lactating dams were used, which were 
alternated between hyperoxia and room air every 24 hours. A murine model of hyperoxia-
induced BPD was used as described in the literature.44,51 Briefly, newborn mice were 
exposed to hyperoxia (100% O2) from postnatal day (PN) 1-4, during the saccular stage of 
murine lung development. A subgroup of animals were sacrificed on PN5 for lung protein 
analysis. Mice were returned to room air and allowed to recover until the BPD phenotype 
developed (circa PN14).51 Mice were then sacrificed on PN14 to assess lung morphology. 
All animal work was approved by the Institutional Animal Care and Use Committee at the 
Yale University School of Medicine (New Haven, CT). The author received help with animal 
care, siRNA administration, and oxygen exposure. All other animal work was carried out 
by the author. 
siRNA administration.  Ang2 siRNA (20 μM) was prepared in either RNase-free water or 
Curosurf®. One to two drops of these solutions was introduced intranasally into the 
pulmonary tree of newborn mice on PN1 and PN3. 
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Oxygen exposure.  Newborn mice were placed in cages in an airtight Plexiglas chamber 
(55 × 40 × 50 cm3) ventilated with 100% O2. Oxygen levels were monitored throughout 
via a sensor connected to a relay switch integrated into the oxygen supply circuit. 
Hyperoxia exposure was initiated on PN1 and continued through PN4. 
Protein isolation and detection.  Mice were sacrificed using standard CO2 protocol. 
Median sternotomy was performed and right heart perfusion with PBS was done to clear 
the pulmonary intravascular space. The lungs were rapidly removed en bloc and frozen in 
liquid nitrogen. Tissue samples were added to RIPA buffer solution and homogenized with 
an electric homogenizer. Following incubation, lysates were centrifuged and supernatant 
containing whole protein was collected. Lung lysates were analyzed for protein content 
as described above. 
Histology.  Lung tissues obtained from newborn mice at PN14 were subjected to a 
standard protocol for lung inflation (25 cm) and fixed overnight in 10% buffered formalin. 
The fixed tissues were then embedded in paraffin, sectioned (5 μm), and hematoxylin & 
eosin stained by the Research Histology Laboratory of the Department of Pathology at 
Yale University School of Medicine. 
Lung morphometry.  Alveolar size was estimated from the mean chord length of the 
airspace, as the chord length increases proportionally with alveolar enlargement.52 
Images were obtained using an Olympus IX70 fluorescence microscope at 10x 
magnification and cellSens imaging software (Olympus Corp).  A minimum of 3 fields per 
mouse were obtained. Each field was analyzed on a Macintosh computer using a modified 
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custom macro in NIH Image (National Institutes of Health).53 Briefly, images were run 
through an automated algorithm which processed the images via threshold, smoothing, 
and inversion. The processed images were then subjected to logical image match ‘and’ 
operations with horizontal and vertical grids. At least 200 measurements per field were 
made for each animal. The length of the lines overlying air space was averaged as the 
mean chord length. 
Statistical Analysis 
Data are expressed as the mean ± standard error of the mean (SEM). A minimum of 3 
samples per group was used. As appropriate, groups were compared with an unpaired 
two-tailed Student’s t-test with GraphPad Prism 6.03 (GraphPad Software Inc, San Diego, 







Effect of Curosurf® on siRNA transfection in MLE-12 cells 
The phenomena of gene silencing expression via RNA interference is dependent on 
effective transfection of siRNA. Hence, we first wanted to assess the efficacy of Curosurf® 
as a transfection reagent with fluorescent-labeled scrambled siRNA. Lipofectamine 2000® 
was used as a positive control as it is known to have very good transfection efficiency. 
MLE-12 cells, a pulmonary adenocarcinoma cell line with alveolar ell characteristics, were 
selected as a surrogate for alveolar epithelial cells. 
As expected, immunofluorescent analysis revealed that detection of scrambled siRNA 
within cells was dependent on the use of a transfection reagent (Fig. 1A). Lipofectamine 
2000® had a transfection rate of 53%, over a 30-fold increase in efficiency when compared 
to siRNA alone (P ≤ 0.0001; Fig. 1B). Among the Curosurf® groups, cells treated with 10 
μL had the highest transfection rate at 4.5% (P ≤ 0.0001; Fig. 1B). Cells treated with 20 μL 
Curosurf® actually had a slight decrease in transfection efficiency when compared to 
siRNA alone (P < 0.05; Fig. 1B). Taken together, these studies show that at proper 





Figure 1.  In vitro effect of Curosurf® on siRNA transfection. (A) Representative fluorescence microscopy 
images for (1) untreated, (2) scrambled siRNA, (3) siRNA and Lipofectamine 2000®, (4) siRNA and 5 μL 
Curosurf®, (5) siRNA and 10 μL Curosurf®, and (6) siRNA and 20 μL Curosurf®. Red areas indicate presence 
of siRNA. (B) Transfection ratios for each group. Each bar represents the mean ± the SEM for a minimum of 
3 samples per group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, unpaired t-test. (Curo = Curosurf®, 
Lipo = Lipofectamine 2000®) 
 
Curosurf® as a transfection reagent on CHOP expression in MLE-12 cells 
Elevated levels of CHOP are associated with cell death via the ER stress-dependent 
pathway in the hyperoxia-induced model of BPD.44 Hence, we wanted to evaluate the use 
of Curosurf® to augment gene silencing using CHOP siRNA. CHOP protein expression was 
assessed by western blot analysis (Fig. 2A). Exposure to hyperoxia resulted in an increase 
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in CHOP when compared to room air. Both Lipofectamine 2000® and Curosurf® treated 
groups benefited from a decrease in CHOP protein expression when compared to 
untreated hyperoxia and naked siRNA (P ≤ 0.05; Fig. 2B). There was no difference 
between the Curosurf® and Lipofectamine 2000® treated groups, suggesting comparable 
efficiency in gene silencing. Interestingly, there was no appreciable difference between 
hyperoxia and naked siRNA groups. Thus, when used as a transfection reagent, Curosurf® 




Figure 2.  In vitro effect of Curosurf® as a transfection reagent on CHOP expression in hyperoxic exposure. 
(A) The protein expression of CHOP in MLE-12 cells was ascertained under the conditions described, with 
β-actin controls. (B) Corresponding relative CHOP protein expression in MLE-12 cells. Each bar represents 
the mean ± the SEM for a minimum of 3 samples per group. *P ≤ 0.05, **P ≤ 0.01, unpaired t-test. (Curo = 







Figure 3.  In vitro effect of Curosurf® as a transfection reagent on Ang2 expression in hyperoxic exposure. 
(A) The protein expression of Ang2 in MLE-12 cells was ascertained under the conditions described, with β-
actin controls. (B) Corresponding relative Ang2 protein expression in MLE-12 cells. Each bar represents the 
mean ± the SEM for a minimum of 3 samples per group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, unpaired t-
test. (Curo = Curosurf®, Hyp = hyperoxia, Lipo = Lipofectamine 2000®, siAng2 = Ang2 siRNA) 
 
Curosurf® as a transfection reagent on Ang2 expression in MLE-12 cells 
Ang2 is an important mediator of epithelial cell death in the hyperoxia-induced model of 
BPD.45 Therefore, we wanted to evaluate the potential use of Curosurf® to augment gene 
silencing using Ang2 siRNA. Ang2 protein expression was assessed by western blot 
analysis (Fig. 3A). Exposure to hyperoxia resulted in an increase in Ang2 when compared 
to room air. Both Lipofectamine 2000® and Curosurf® treated groups benefited from a 
decrease in Ang2 expression when compare to untreated hyperoxia (P ≤ 0.001 and P ≤ 
0.01, respectively; Fig. 3B). There was no difference between the Curosurf® and 
25 
 
Lipofectamine 2000® treated groups, suggesting comparable efficiency in gene silencing. 
Interestingly, there was an appreciable difference between hyperoxia and naked siRNA 
groups but it did not reach statistical significance. There was a significant decrease in 
protein expression when comparing naked siRNA to Lipofectamine 2000® and Curosurf® 
(P ≤ 0.05; Fig. 3B). Thus, when used as a transfection reagent, Curosurf® serves as a potent 
enhancer of Ang2 gene silencing via RNA interference. 
Curosurf® as a transfection reagent on cleaved caspase 3 expression in MLE-12 cells 
Studies have shown that hyperoxia exposure causes cellular injury in alveolar epithelial 
cells and induces cell death.25-27 Caspase 3 is an executioner protease zymogen that plays 
a central role in the activation of cellular death via the intrinsic, extrinsic, and UPR 
pathways.32,54 Since cleaved caspase 3 correlates directly with cell death, we wanted to 
evaluate the expression of cleaved caspase 3 in cells transfected using Curosurf®. 
Cleaved caspase 3 protein expression was assessed by western blot analysis. Cells treated 
with CHOP siRNA alone did not experience an appreciable decrease in cleaved caspase 3 
expression (Fig. 4A). Qualitatively, Curosurf® appears to enhance attenuation of cleaved 
caspase 3 when compared to CHOP siRNA alone (Fig. 4A). Cells treated with Ang2 siRNA 
alone did not experience an appreciable reduction in cleaved caspase 3 expression (Fig. 
4B). Qualitative analysis suggests that transfection with Curosurf® appears to offer a 
considerable reduction of cleaved caspase 3 expression when compared to cells treated 
with Ang2 siRNA alone (Fig. 4B). Thus, transfection with CHOP/Ang2 siRNA using 
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Figure 4.  In vitro effect of Curosurf® as a transfection reagent on cleaved caspase 3 expression in hyperoxic 
exposure. (A) The protein expression of cleaved caspase 3 in CHOP siRNA transfected MLE-12 cells, with β-
actin controls. (B) The protein expression of cleaved caspase 3 in Ang2 siRNA transfected MLE-12 cells, with 
β-actin controls. (C. Casp 3 = cleaved caspase 3, Curo = Curosurf®, Lipo = Lipofectamine 2000®, siAng2 = 
Ang2 siRNA, siCHOP = CHOP siRNA) 
 
Curosurf® as a transfection reagent on Ang2 expression in mice 
 A murine hyperoxia model of BPD was chosen as previous research has shown that 
anatomical and functional changes found in this model mimic those found in human 
disease.26,51,55 Ang2 expression was assessed by western blot analysis. Among mice 
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treated with Ang2 siRNA, protein expression appears to be attenuated when transfected 
with and without Curosurf® (Fig. 5). Qualitative analysis suggests that treatment with 
Ang2 siRNA alone appears to offer comparable Ang2 gene silencing when compared to 




Figure 5.  In vivo effect of Curosurf® as a transfection reagent on Ang2 expression in hyperoxic exposure. 
The protein expression of Ang2 in C57BL/6 mice was ascertained under the conditions described, with β-
actin controls. (Curo = Curosurf®, siAng2 = Ang2 siRNA) 
 
Effect of Curosurf® as a transfection reagent on mouse lung morphology 
BPD lung morphology is characterized by impaired alveolarization secondary to cellular 
injury and inflammation.7 Histologic sections of lung tissue from PN14 mice exposed to 
hyperoxia exhibit characteristic enlarged, simplified alveoli (Fig. 6A, Panel 2). The lung 
architecture is better preserved in mice treated with Ang2 siRNA with improved 
alveolarization (Fig. 6A, Panel 3). Additionally, mice treated with Ang2 siRNA and 
Curosurf® seemed to respond with further improvement in alveolarization when 






Figure 6.  Effect of Curosurf® as a delivery vehicle for Ang2 siRNA on pulmonary phenotype. (A) 
Representative microscopy images of pulmonary structure in PN14 WT mice exposed to (1) room air, (2) 
hyperoxia, (3) hyperoxia treated with siAng2, and (4) hyperoxia treated with siAng2 and Curosurf®. (B) 
Mean chord length for each group. Each bar represents the mean ± the SEM for a minimum of 3 samples 
per group. *P ≤ 0.05, **P ≤ 0.01, unpaired t-test. (Curo = Curosurf®, Hyp = hyperoxia, PN = postnatal, WT = 
wild-type) 
 
The degree of alveolarization can be characterized quantitatively because alveolar size is 
directly proportional to chord length.52 Mean chord length of PN14 mice treated with 
Ang2 siRNA alone was decreased when compared to the hyperoxia model of BPD; 
however, this difference was not statistically significant (P = 0.095; Fig. 6B). Mean chord 
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length of mice treated with Ang2 siRNA and Curosurf® was decreased when compared to 
both hyperoxia and siRNA alone (P ≤ 0.05; Fig. 6B). Thus, Curosurf® enhances gene 






The use of siRNA therapy in the treatment of BPD offers many advantages and can act in 
concert with other treatment modalities. The central premise of siRNA therapy is 
interruption of key inflammatory cascade components that lead to impaired 
vascularization and alveolarization. RNA interference has the advantage of gene silencing 
without altering host DNA. Exogenous nucleic acids introduced into the host are 
temporary – they act transiently and are degraded by host RNases. An added benefit of 
using RNA interference is the ability to directly targeting the lung when administering 
siRNA intranasally. Thus, siRNA therapy is suited for a disease of the premature neonate 
as it protects the developing lung until the patient is capable of being weaned from 
respiratory support. 
Although the use commercially available transfection reagents to enhance transfection in 
siRNA therapy is appealing, these reagents are not cleared for clinical use in the United 
States. Additionally, studies have shown that these transfection reagents can have 
significant cytotoxicity.56,57 Moreover, cationic liposomes cause a release of reactive 
oxygen species and induce a marked inflammatory response in pneumocytes.46 This 
necessitates the need to explore other transfection enhancing candidates such as 
Curosurf®. 
Properties of Curosurf® 
Curosurf® is unique among the exogenous surfactants currently approved by the FDA for 
clinical use in the United States. It is the only natural surfactant extracted from porcine 
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lung. Studies have suggested that porcine derived surfactants are most similar in 
composition to human surfactant with regards to phosphatidylcholine content.49 
However, the relevance of this similarity to clinical practice remains to be investigated. 
Furthermore, due to mincing of whole lung in the extraction process, Curosurf® has a 
significantly higher proportion of sphingomyelin.49 Orborina et al have shown that 
sphingomyelin is resistant to oxidation, particularly when compared to 
phosphatidylcholines like dipalmitoylphosphatidylcholine (DPPC).58 DPPC is a common 
additive in many commercial surfactant preparations; however it is not added to 
Curosurf®.49 Thus, in addition to its role as a transfection reagent, Curosurf® itself may 
offer direct protection against oxidative damage. 
Like the other commercially available surfactants, preparations of Curosurf® lack 
surfactant protein SP-A since it is removed in the lipid extraction process.49 SP-A is found 
in abundance in natural surfactant and plays an important role in surfactant recycling via 
receptor-mediated endocytosis at Type II alveolar cells.19-21 The relatively low transfection 
efficiency of Curosurf® in our experiments may be partially attributed to this lack of SP-A. 
The use of native SP-A is restricted secondary to limitations imposed by its size and 
solubility in isolation and recovery. Animal experiments using surfactant enriched with a 
synthetic SP-A analogue have shown superiority in improved lung compliance over 
surfactant deficient in SP-A.59 However, the effect on surfactant reuptake was not 
investigated. The use of Curosurf® preparations enriched with synthetic SP-A in siRNA 
therapy is something that could be investigated in future studies. 
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Hyperoxic injury during the late canalicular/early saccular phase of lung development has 
been implicated in the pathogenesis of BPD.27 Hence, we decided to investigate the use 
of Curosurf® in RNA interference using two mediators of cell death in BPD: CHOP and 
Ang2. These two proteins were chosen because they act upon differing pathways that 
ultimately lead to inflammation and hyperoxia-induced cell death. 
Curosurf® as a transfection reagent in vitro 
Internalization of naked RNA is inefficient in cell cultures because negatively charged 
oligonucleotides have to cross the hydrophobic cell membrane. Transfection regents such 
as Lipofectamine 2000® can enhance internalization by an order of magnitude or more. 
In our study, Lipofectamine 2000® improved transfection by 30 fold, whereas Curosurf® 
had a transfection rate of 4.5% – a modest 2.5 fold improvement over naked siRNA (Fig. 
1). Despite this, transfection with Curosurf® proved to have a potent effect on gene 
silencing (Fig. 2 & Fig. 3). Moreover, Lipofectamine 2000® has the potential for 
considerable cytotoxicity.46,56 Curosurf® on the other hand is relatively innocuous – 
animal studies and clinical trials have shown that it has a low cytotoxic profile.60-62 Taken 
together, this makes Curosurf® an appealing candidate for use in siRNA therapy. 
Cleaved caspase 3 expression, a marker of cell death, was also attenuated with Curosurf® 
enhanced siRNA therapy in vitro (Fig. 4). Hence, although the transfection efficiency of 
Curosurf® is relatively low when compared to Lipofectamine 2000®, it had an appreciable 
effect on suppressing cell death. This suggests that RNA interference is sensitive to even 
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modest increases in siRNA internalization – small improvements in transfection efficiency 
can markedly prevent cell death. 
Choo-Wing et al have previously investigated the relationship between CHOP expression 
and cell death in alveolar epithelial cells exposed to hyperoxia.44 They found that CHOP 
siRNA reduced CHOP protein expression and cell death in MLE-12 cells exposed to 24 h 
hyperoxia. Our studies did not show a decrease in CHOP protein expression with naked 
siRNA alone. However, we did find that administration of CHOP siRNA with Curosurf® 
significantly reduced CHOP protein expression (Fig. 2). This difference is likely due to our 
higher seeded cell count, resulting in a higher cell density and relatively low dose of siRNA 
in our experiments. Although not measured directly, our work suggests that cell death 
would also be ameliorated as levels of cleaved caspase 3 are reduced when Curosurf® is 
employed as a transfection reagent (Fig. 4A). Hence, our results suggest that Curosurf® 
has a marked effect on enhancing CHOP gene silencing, decreasing cell death. 
The use of Ang2 siRNA has not been investigated in MLE-12 cells. Our results suggest that 
internalization of Ang2 siRNA is inefficient without the use of a transfection reagent. 
Although the protein expression of Ang2 was decreased relative to hyperoxia, it was not 
found to be statistically significant (P = 0.26, Fig. 3). However, Curosurf® enhanced the 
transfection efficacy of Ang2 siRNA as evidenced by the decrease in protein expression 
(Fig. 3). Cleaved caspase 3 was also attenuated with Curosurf®, suggesting a reduction in 
cell death (Fig. 4B). Transfection with naked siRNA alone did not reduce cleaved caspase 
3 expression. The findings suggest that in vitro transfection of naked siRNA is ineffective, 
whereas Curosurf® significantly enhances transfection efficiency. 
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Curosurf® as a transfection reagent in vivo 
Numerous in vivo studies have shown modest internalization of naked oligonucleotides 
without the use of a transfection reagent.63,64 Furthermore, RNA interference therapy 
using naked siRNA in animal models of BPD has been reported in the literature.44,45,55 Prior 
studies investigating Ang2 siRNA therapy have used young adult mice (4-6 weeks of age) 
in their BPD models.45,55 The temporal regulation of various angiopoietins plays a key role 
in pulmonary vascular network development.35 Hence, the use of appropriately aged 
specimens is crucial when investigating animal models of BPD. To our knowledge, the data 
we present herein marks the first time that newborn mice with a hyperoxia-induced 
model of BPD were used to evaluate the efficacy of Ang2 siRNA therapy. 
As mentioned earlier, Ang2 destabilizes blood vessels, induces vascular regression, and 
induces endothelial cell apoptosis.27 Bhandari et al previously investigated the 
relationship between Ang2 expression and acute lung injury.45,55 They found that 
administration of naked Ang2 siRNA reduced protein expression, BAL cellularity, and 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cell death 
in a murine model of hyperoxia-induced BPD.45 Our animal studies also suggest that Ang2 
expression is attenuated with Ang2 siRNA therapy. Surprisingly, this reduction is 
comparable between naked siRNA and Curosurf® enhanced transfection (Fig. 5). 
However, analysis of lung morphology reveals that only mice transfected using Curosurf® 
had a further significant preservation of lung architecture compared to naked siRNA alone 
(Fig. 6). One explanation for this may be the inherent differences between the in vivo and 
in vitro transfection processes. Furthermore, Curosurf® may play a more significant role 
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in facilitating effective distribution of siRNA to the alveoli than enhancing siRNA 
transfection into Type II pneumocytes. 
In sum, our research demonstrates that Curosurf® has a modest effect on the 
internalization of CHOP/Ang2 siRNA in transfection experiments. We subsequently 
appreciated a significant decrease in CHOP/Ang2 protein expression, cleaved caspase 3 
expression, and improved lung alveolarization. A proposed sequence of events 
summarizing these results is illustrated below (Fig. 7). 
 
 
Figure 7.  Proposed pathway for the effects of siRNA in vivo and in vitro. Hyperoxia leads to increased 
expression of CHOP/Ang2, which is decreased with naked siRNA against those two specific genes. This leads 
to decreased cleaved caspase 3, resulting in decreased cell death and improved alveolarization. In the right 
panel, use of Curosurf® as a delivery vehicle for CHOP/Ang2 siRNA augments the decreased expression of 




Limitations and Future Work 
The animal work presented here is limited due to low numbers of mice in each group 
(n≥3). Repeating the studies with larger cohorts should provide enough power to resolve 
whether or not there is a significant difference in Ang2 protein expression in mice 
transfected with and without Curosurf®. Given the improved lung morphology in mice 
treated with Curosurf®, we expect that there should indeed be a difference. Although not 
covered in our study due to time constraints, investigation is warranted into the effect of 
Curosurf® enhanced delivery of CHOP siRNA in newborn mice – specifically, the effect on 
hyperoxia-induced pulmonary damage. Furthermore, future studies expanding on the 
concepts presented here should include a Curosurf®-only control in order to assess 
whether the beneficial effect of Curosurf® enhanced siRNA therapy is in part due to 
Curosurf® itself. 
We expect that our protocol for Curosurf® enhanced Ang2 siRNA delivery in vivo could be 
generalized for any oligonucleotide sequence. This opens up the possibility of testing 
Curosurf® enhanced siRNA delivery of many other causal biomarkers and proteins of 
interest. It would also be interesting to compare transfection rates of other commercially 
available surfactants to Curosurf®. 
There are a number of studies that can add to our understanding of how Curosurf® 
enhanced siRNA therapy effects the development of BPD. Bronchoalveolar lavage (BAL) 
can be performed prior to lung harvest to assess the degree of inflammation. Neutrophil 
counts of the BAL fluid give an indication of the degree of inflammation and is thus 
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appropriate in ascertaining if Ang2 siRNA ameliorates inflammation. Additionally, the 
effect on angiogenesis of the microvasculature should be investigated. This can be 
performed in vivo via the use of antibodies against endothelial markers such as platelet 
endothelial cell adhesion molecule (PECAM). Finally, plasticity and degree of dysplasia can 
be assessed by measuring the Type II epithelial cell count via flow cytometry. Type II 
pneumocytes serve as progenitor cells in the lung and play an essential role during normal 
lung development. 
Bourbon et al have shown some success with the reuptake of surfactant components 
using Curosurf®.22 In their studies, liposomes were prepared by sonication of the 
suspension for 30 s∙min-1 over a 15 min period. Future RNA interference studies using 
Curosurf® may benefit from the use of sonication to facilitate siRNA-laden liposome 
formation. Furthermore, as stated earlier, SP-A is thought to be an important mediator in 
receptor-mediated endocytosis at Type II alveolar epithelial cells. Enrichment of 
Curosurf® with synthetic SP-A may also yield an improvement in transfection ratio in 
future studies.59  
Conclusion 
In summary, our data shows a modest but significant improvement in mouse lung 
morphology when Curosurf® is used to enhance Ang2 siRNA delivery in a hyperoxia-
induced model of BPD. Our in vitro work with CHOP also suggests that cell death is better 
mitigated with Curosurf® enhanced CHOP siRNA delivery. Possible mechanisms for the 
observed improvement includes better alveolar distribution of therapeutic siRNA, 
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improved surfactant/oligonucleotide uptake by Type II pneumocytes, and intrinsic 
antioxidative protection offered by Curosurf®. Further studies are needed to optimize and 
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